Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Equity Average (2016 - 2025)

Historic Equity Average for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to $476.2 million.

  • Vanda Pharmaceuticals' Equity Average fell 1212.57% to $476.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $476.2 million, marking a year-over-year decrease of 1212.57%. This contributed to the annual value of $541.7 million for FY2024, which is 105.85% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Equity Average stood at $476.2 million, which was down 1212.57% from $498.9 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Equity Average registered a high of $544.5 million during Q1 2024, and its lowest value of $460.4 million during Q1 2021.
  • Its 5-year average for Equity Average is $515.2 million, with a median of $521.4 million in 2022.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Equity Average soared by 1189.63% in 2021 and then plummeted by 1212.57% in 2025.
  • Vanda Pharmaceuticals' Equity Average (Quarter) stood at $499.1 million in 2021, then grew by 4.47% to $521.4 million in 2022, then increased by 4.33% to $544.0 million in 2023, then decreased by 0.76% to $539.9 million in 2024, then decreased by 11.8% to $476.2 million in 2025.
  • Its Equity Average stands at $476.2 million for Q3 2025, versus $498.9 million for Q2 2025 and $525.0 million for Q1 2025.